Literature DB >> 26991125

Opposing role of tumor necrosis factor receptor 1 signaling in T cell-mediated hepatitis and bacterial infection in mice.

Raluca Wroblewski1,2, Marietta Armaka3, Vangelis Kondylis4,5,6, Manolis Pasparakis4,5,6, Henning Walczak7, Hans-Willi Mittrücker2,8, Christoph Schramm1,2, Ansgar W Lohse1,2, George Kollias3,9, Hanno Ehlken1,2,10.   

Abstract

UNLABELLED: Death receptor (DR) ligands such as tumor necrosis factor (TNF) have been identified as fundamental mediators of liver damage both in mouse models and in humans. While the essential site of function of DR signaling is conceivably the hepatocyte, a systematic analysis is missing. Using mice with conditional gene ablation, we analyzed the tissue-specific function of DR signaling in T cell-dependent (concanavalin A) and independent (lipopolysaccharide/galactosamine) hepatitis and in models of bacterial infection (Listeria monocytogenes, lipopolysaccharide). We report that lipopolysaccharide/galactosamine-induced liver injury depends on hepatocyte-intrinsic TNF receptor 1 (p55, TNFR1). In contrast, we show that T cell-induced hepatitis was independent of TNFR1 signaling in hepatocytes, T cells, or endothelial cells. Moreover, T cell-induced hepatitis was independent of hepatocyte-intrinsic Fas-associated protein with death domain, TNF-related apoptosis-inducing ligand receptor, or Fas signaling. Instead, concanavalin A-induced hepatitis was completely prevented in mice with myeloid-derived cell (MDC)-specific deletion of TNFR1. Significantly, however, mice lacking TNFR1 in MDCs succumbed to listeria infection, although they displayed similar sensitivity toward endotoxin-induced septic shock when compared to control mice. These results suggest that TNFR1 signaling in MDCs is a critical mediator of both the detrimental and the protective functions of TNF in T cell-induced hepatitis and bacterial infection, respectively.
CONCLUSION: The critical site of action of DRs is completely dependent on the nature of hepatitis; the data specify MDCs as the essential cell type of TNFR1 function in T cell-mediated hepatitis and in the response to listeria, thereby identifying the opposing role of MDC TNFR1 in autoimmunity and bacterial infection. (Hepatology 2016;64:508-521).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26991125     DOI: 10.1002/hep.28551

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

1.  Preclinical studies of a death receptor 5 fusion protein that ameliorates acute liver failure.

Authors:  Qian Chen; Pu Wang; Qingmei Zhang; Meng Xia; Guizhong Zhang; Junxin Li; Enyun Shen; Youhai H Chen; Xiaochun Wan
Journal:  J Mol Med (Berl)       Date:  2019-06-22       Impact factor: 4.599

2.  TNFR2 Depletion Reduces Psoriatic Inflammation in Mice by Downregulating Specific Dendritic Cell Populations in Lymph Nodes and Inhibiting IL-23/IL-17 Pathways.

Authors:  Unnikrishnan M Chandrasekharan; Raminderjit Kaur; Jennifer E Harvey; Chad Braley; Vandana Rai; MacKenzie Lee; Nicholas de Windt; Jason Hsieh; Ritika Jaini; Defne Bayik; Rachel G Scheraga; Anthony P Fernandez; Paul E DiCorleto; M Elaine Husni
Journal:  J Invest Dermatol       Date:  2022-01-26       Impact factor: 7.590

3.  RIPK1 protects from TNF-α-mediated liver damage during hepatitis.

Authors:  Aveline Filliol; Claire Piquet-Pellorce; Jacques Le Seyec; Muhammad Farooq; Valentine Genet; Catherine Lucas-Clerc; John Bertin; Peter J Gough; Marie-Thérèse Dimanche-Boitrel; Peter Vandenabeele; Mathieu Jm Bertrand; Michel Samson
Journal:  Cell Death Dis       Date:  2016-11-10       Impact factor: 8.469

4.  RIPK1 protects hepatocytes from death in Fas-induced hepatitis.

Authors:  Aveline Filliol; Muhammad Farooq; Claire Piquet-Pellorce; Valentine Genet; Marie-Thérèse Dimanche-Boitrel; Peter Vandenabeele; Mathieu J M Bertrand; Michel Samson; Jacques Le Seyec
Journal:  Sci Rep       Date:  2017-08-23       Impact factor: 4.379

Review 5.  Crosstalk of liver immune cells and cell death mechanisms in different murine models of liver injury and its clinical relevance.

Authors:  Hilal Ahmad Khan; Muhammad Zishan Ahmad; Junaid Ali Khan; Muhammad Imran Arshad
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2017-06

6.  The concentration of tumor necrosis factor-α determines its protective or damaging effect on liver injury by regulating Yap activity.

Authors:  Shanmin Zhao; Jinghua Jiang; Yingying Jing; Wenting Liu; Xue Yang; Xiaojuan Hou; Lu Gao; Lixin Wei
Journal:  Cell Death Dis       Date:  2020-01-27       Impact factor: 8.469

7.  NOD1 Agonist Protects Against Lipopolysaccharide and D-Galactosamine-Induced Fatal Hepatitis Through the Upregulation of A20 Expression in Hepatocytes.

Authors:  Fang Jia; Fuxue Deng; Pan Xu; Shiying Li; Xuefu Wang; Peng Hu; Hong Ren; Shiwen Tong; Wenwei Yin
Journal:  Front Immunol       Date:  2021-03-04       Impact factor: 7.561

Review 8.  Role of the Interaction of Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors 1 and 2 in Bone-Related Cells.

Authors:  Hideki Kitaura; Aseel Marahleh; Fumitoshi Ohori; Takahiro Noguchi; Yasuhiko Nara; Adya Pramusita; Ria Kinjo; Jinghan Ma; Kayoko Kanou; Itaru Mizoguchi
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

9.  Ameliorative Effect of Pomegranate Peel Extract (PPE) on Hepatotoxicity Prompted by Iron Oxide Nanoparticles (Fe2O3-NPs) in Mice.

Authors:  Yasmin M Abd El-Aziz; Basma M Hendam; Fawziah A Al-Salmi; Safa H Qahl; Eman H Althubaiti; Fahmy G Elsaid; Ali A Shati; Nasser M Hosny; Eman Fayad; Ali H Abu Almaaty
Journal:  Nanomaterials (Basel)       Date:  2022-09-04       Impact factor: 5.719

10.  OTUB1 prevents lethal hepatocyte necroptosis through stabilization of c-IAP1 during murine liver inflammation.

Authors:  Josephin Koschel; Gopala Nishanth; Sissy Just; Kunjan Harit; Andrea Kröger; Martina Deckert; Michael Naumann; Dirk Schlüter
Journal:  Cell Death Differ       Date:  2021-03-12       Impact factor: 15.828

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.